AbbVie

$83.10
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.36 (-1.61%) Today
+$0.21 (+0.25%) As of 7:51 AM EDT after-hours

Why Robinhood?

You can buy or sell AbbVie and other stocks, options, and ETFs commission-free!

About ABBV

ABBVIE INC., also called AbbVie, is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. Read More The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. The listed name for ABBV is ABBVIE INC.

Employees
30,000
Headquarters
North Chicago, Illinois
Founded
2011
Market Cap
146.29B
Price-Earnings Ratio
17.92
Dividend Yield
5.47
Average Volume
7.70M
High Today
$84.14
Low Today
$82.56
Open Price
$83.47
Volume
9.78M
52 Week High
$101.28
52 Week Low
$62.55

Collections

ABBV News

MarketWatchOct 16

Study finds remdesivir, hydroxychloroquine have 'little' impact on mortality in COVID-19 patients

A clinical trial conducted by the World Health Organization found that Gilead Sciences Inc.'s remdesivir, hydroxychloroquine, AbbVie's ABBV, +1.22% lopinavir/ri

ABBV Earnings

$0.00
$0.92
$1.85
$2.77
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
$2.77 per share
Actual
Available Oct 30, Pre-Market

You May Also Like